Latest news for AllStar Health Brands (OTC:ALST) Stock

AllStar Health Brands Inc is a pharmaceutical company. It is engaged in the distribution and selling of pharmaceutical and natural health products. The product portfolio of the company includes SunVeil Active Plus, SunVeil Soie Neutre, Sunveil crema, BerbereX Wound Cleanser, and BerbereX Foot & Leg Cream.

Photo by Hermes Rivera on Unsplash

Cannabis

News

Penny Stocks

Commodities

Markets

Real Estate

ALLSTAR HEALTH BRANDS by Allstar Health Brands, Inc.

ALST

SNNC

Sibannac, Inc. Eyes Canadian Cannabis Market With AllStar Health-Tyme Partnership

ALLSTAR HLTH BRANDS INC by Allstar Health Brands, Inc.

AllStar Health Brands Inc

Alstom SA

ALSTRIA OFFICE AG ORD by Alstria Office AG, Hamburg

alstria office REIT-AG

<a href="https://x.com/OpenAI/status/1882876172339757392" title="https://x.com/OpenAI/status/1882876172339757392">https://x.com/OpenAI/status/1882876172339757392</a>

MSFT

OpenAI Posts On X "Canvas update: today we're rolling out a few highly-requested updates to canvas in ChatGPT...."

3M's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MMM#NYSE">MMM</a>) short percent of float has risen 8.11% since its last report. The company recently reported that it has 6.50 million shares sold short, which is 1.2% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.27 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>3M Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1737747923_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for 3M has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing 3M's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, 3M's peer group average for short interest as a percentage of float is 4.65%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Trading Ideas

Looking Into 3M's Recent Short Interest

Sanofi's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NYSE">SNY</a>) short percent of float has risen 11.76% since its last report. The company recently reported that it has 4.21 million shares sold short, which is 0.19% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.64 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Sanofi Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1737747918_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Sanofi has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Sanofi's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Sanofi's peer group average for short interest as a percentage of float is 4.20%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

How Is The Market Feeling About Sanofi?

General Dynamics's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GD#NYSE">GD</a>) short percent of float has risen 16.78% since its last report. The company recently reported that it has 4.10 million shares sold short, which is 1.67% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.33 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>General Dynamics Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1737747913_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for General Dynamics has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing General Dynamics's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, General Dynamics's peer group average for short interest as a percentage of float is 3.70%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Looking Into General Dynamics's Recent Short Interest

Wall Street paused for a breather on Friday, with the S&amp;P 500 index hovering around the flatline at midday trading in New York after a five-day rally that pushed the market to fresh record highs this week. Meanwhile, investor attention shifted to <a href="https://www.benzinga.com/markets/forex">forex and gold markets.</a>
The greenback is experiencing its worst weekly performance since July 2023, as President Donald Trump refrained from imposing new tariffs during his first week and escalated pressure on the Federal Reserve, urging the central bank to lower interest rates. The U.S. dollar index – tracked by the Invesco DB USD Index Bullish Fund ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UUP#NYSE">UUP</a>) – dropped 0.7% on Friday, extending its weekly decline to 1.7%.
Adding to the dollar's downward momentum, the Bank of Japan raised interest rates by 25 basis points to 0.5%, the highest level since 2008, in a move that broadly met expectations.
Gold capitalized on the dollar's weakness and rising tensions between the president and the central bank, marking another week of strong gains and approaching all-time highs. The bullion, tracked by the SPDR Gold Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GLD#NYSE">GLD</a>), was trading at $2,777 per ounce.
On the macro front, S&amp;P Global reported a slowdown in private sector growth in January, as the services sector faced an unexpected setback, despite manufacturing expanding for the first<a href="https://www.benzinga.com/economics/macro-economic-events/25/01/43195427/us-services-growth-slows-manufacturing-finally-expands-in-january-inflation-was-broad-based-expert-warns"> time in seven months.</a>
A warning came from the University of Michigan's consumer survey, which downwardly revised the January consumer confidence indicator and pointed to increasing trends of households making purchases in advance to avoid potential price hikes <a href="https://www.benzinga.com/economics/macro-economic-events/25/01/43197024/consumer-confidence-declines-as-buying-in-advance-trends-grow">linked to tariffs.</a>
In the cryptocurrency market, Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) climbed 2.5% following Trump's executive order signed on Thursday, aimed at strengthening U.S. leadership in digital assets. 
<h3 class="wp-block-heading">Friday&#8217;s Performance In Major US Indices, ETFs</h3>
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Major Indices</td>
<td>Price</td>
<td>1-day %chg</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>2,314.96</td>
<td>0.0%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>6,119.65</td>
<td>0.0%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>44,541.76</td>
<td>-0.1 %</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>21,861.02</td>
<td>-0.2%</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Updated at 1:00 p.m. ET</figcaption></figure>
According to&nbsp;<a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent012425&amp;t=be2bearmibe3na1" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>&nbsp;data:
<ul>
<li>The&nbsp;SPDR S&amp;P 500 ETF Trust&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) eased 0.1% to $608.89.</li>
<li>The&nbsp;SPDR Dow Jones Industrial Average&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>)&nbsp;inched 0.1% lower to $444.96.</li>
<li>The tech-heavy&nbsp;Invesco QQQ Trust Series&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) slipped 0.4% to $530.73.</li>
<li>The&nbsp;iShares Russell 2000 ETF&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) stalled at $229.40.</li>
<li>The&nbsp;Utilities Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLU#NYSE">XLU</a>) outperformed, up 0.9%; the&nbsp;Technology Select Sector SPDR Fund&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLE#NYSE">XLE</a>) lagged, down 0.4%.</li>
</ul>
<h3 class="wp-block-heading">Friday&#8217;s Stock Movers</h3>
<ul>
<li>American Express Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AXP#NYSE">AXP</a>) fell 2.4% after reporting fourth-quarter results. </li>
<li>Other stocks moving on quarterly results were Verizon Communications Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VZ#NYSE">VZ</a>), up 1.3%, NextEra Energy Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NEE#NYSE">NEE</a>), up 4%, HCA Healthcare Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HCA#NYSE">HCA</a>), down 3.2%, First Citizens BancShares Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FCNCA#NASDAQ">FCNCA</a>), up 3.1%, Ericsson (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ERIC#NASDAQ">ERIC</a>), down 14.3%, Intuitive Surgical Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISRG#NASDAQ">ISRG</a>), down 3.6%, Texas Instruments Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TXN#NASDAQ">TXN</a>), down 7.1%, and CSX Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSX#NASDAQ">CSX</a>), down 2.8%. </li>
<li>Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) soared 8.1% after new weight loss drug amycretin showed strong trial results. </li>
</ul>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/01/43198272/us-stocks-hit-dot-com-era-valuations-vs-bonds-why-some-experts-remain-bullish">US Stocks Hit Dot-Com Era Valuations Vs. Bonds: Why Some Experts Remain Bullish</a></li>
</ul>
Photo: Shutterstock

Large Cap

Macro Economic Events

Mid Cap

Sector ETFs

Broad U.S. Equity ETFs

Specialty ETFs

Forex

Econ #s

Economics

ETFs

$BTC

SPDR Dow Jones Industrial Average ETF Trust

ERIC

FCNCA

ISRG

PowerShares DB US Dollar Index Bullish Fund

Stocks Stall, Gold Nears Record Highs As Dollar Faces Worst Week Since July 2023: What's Driving Markets Friday?

Goldman Sachs analyst Neil Mehta cut the price forecast for Exxon Mobil Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XOM#NYSE">XOM</a>) from $125 to $123 ahead of the company&#8217;s fourth-quarter results, which will <a target="_blank" href="https://www.benzinga.com/earnings" rel="noreferrer noopener">be reported on January 31, 2025</a>.
The analyst updates ExxonMobil estimates to reflect mark-to-market commodity prices and incremental Upstream guidance, <a target="_blank" href="https://www.benzinga.com/quote/XOM/analyst-ratings" rel="noreferrer noopener">maintaining a Neutral rating</a>.
While the company benefits from strong execution, shareholder returns (~8% capital returns yield in 2025/2026), and premium Upstream assets (Permian, Guyana, LNG), its relative valuation keeps the analyst on the sidelines.
On January 8, the oil giant stated that it anticipates changes in oil prices to reduce&nbsp;fourth-quarter&nbsp;upstream earnings&nbsp;Q/Q&nbsp;by<a target="_blank" href="https://www.benzinga.com/25/01/42875502/oil-price-drop-to-cut-exxon-mobils-q4-upstream-earnings-by-up-to-09-billion" rel="noreferrer noopener"> $(0.9) billion to&nbsp;$(0.5)&nbsp;billion</a>.
On the other hand, Exxon Mobil projects that variations in industry margins will impact energy products earnings by&nbsp;$(0.7)&nbsp;billion – $(0.3)&nbsp;billion, specialty products earnings by $(0.1) billion – $0.1 billion, and chemical products earnings by&nbsp;$(0.5) billion – $(0.3) billion.
The analyst writes that this implies a ~$1.50 EPS midpoint, with Upstream, Downstream, and Chemicals <a target="_blank" href="https://www.benzinga.com/25/01/42883747/goldman-sachs-cuts-exxon-mobils-q4-eps-forecast-cites-weakness-across-segments" rel="noreferrer noopener">earnings below versus prior GS expectations</a>.
Mehta&#8217;s 2024-2026 EPS estimates are revised to $7.63 (from $7.91), $8.17 (from $8.35) and $9.97 (from $9.71), respectively, reflecting mark-to-market commodity prices and refining margins, production adjustments, and pricing realization tweaks.
Investors can gain exposure to XOM via&nbsp;Vanguard Energy ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VDE#NYSE">VDE</a>) and SPDR Select Sector Fund – Energy Select Sector&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLE#NYSE">XLE</a>).
Price Action: XOM shares are down 1.28% at $108.74 at last check Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/01/43087966/trump-signs-orders-to-take-us-out-of-paris-climate-agreement-calls-the-deal-one-sided-and-unfair" target="_blank" rel="noreferrer noopener">Trump Signs Orders To Take US Out Of Paris Climate Agreement, Calls The Deal &#8216;One-Sided&#8217; And Unfair</a></li>
</ul>
Photo via Shutterstock

Analyst Color

Equities

Price Target

Reiteration

Analyst Ratings

Goldman Sachs Stays On The Sidelines On Exxon Mobil - Here's Why

Wall Street analysts raised their price targets on SLM Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLM#NASDAQ">SLM</a>) after the company released its <a target="_blank" href="https://www.benzinga.com/pressreleases/25/01/b43177801/sallie-mae-reports-fourth-quarter-and-full-year-2024-financial-results" rel="noreferrer noopener">fourth-quarter print</a> Thursday amid an exciting earnings season.
SLM&#8217;s fourth-quarter EPS of $0.50 missed the analyst estimate. The net interest income of $362.00 million missed the analyst estimate of $373.96 million.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/01/43191472/broadcom-powers-solidigms-high-capacity-ssds-key-driver-for-ai-and-data-intensive-growth" rel="noreferrer noopener">Broadcom Powers Solidigm&#8217;s High-Capacity SSDs, A Key Driver for AI and Data-Intensive Growth</a>
SLM expects fiscal 2025 EPS of $3.00-$3.10 versus $3.35 analyst estimate. It expects non-interest expenses of $655 million-$675 million.
Keefe, Bruyette &amp; Woods analyst Sanjay Sakhrani maintained SLM with a Market Perform with a <a target="_blank" href="https://www.benzinga.com/quote/SLM/analyst-ratings" rel="noreferrer noopener">price target of&nbsp;$30</a>.
RBC Capital&nbsp;analyst Jon G. Arfstrom reiterated an Outperform on SLM and raised the price target&nbsp;to $32 from $30.
JP Morgan analyst Richard Shane maintained SLM with a Neutral and raised the price target from $29 to $30.
Keefe, Bruyette &amp; Woods: SLM reported core EPS of $0.50, which compares to Sakhrani&#8217;s estimate of $0.58. The miss to the analyst&#8217;s EPS estimate was driven by higher provision (-$0.15/share) and lower net interest income (-$0.01/share), partially offset by lower expenses (+$0.02/share) and a lower tax rate (+$0.06/share).
SLM reported a miss relative to Sakhrani&#8217;s expectations on higher provisions, while Pre-provision Net Revenue (PPNR) aligned with expectations. Core trends were mixed, with originations and the Delinquency (DQ) rate being better, PPNR and the net charge-off (NCO) rate being in line, and the Net interest margin rate being weaker. The company provided a 2025 outlook with EPS and loan origination growth better than Sakhrani&#8217;s expectations, while the NCO rate and expenses are in line.
RBC Capital: Core results were acceptable in a seasonally softer origination quarter. Highlights included substantial loan growth, some modest margin reduction, and a meaningful decrease in expense levels. Credit trends were more mixed with higher NCOs sequentially, though management remains hopeful that losses should continue to normalize lower in 2025 towards its longer-term loss range. 
The 2025 outlook calls for solid origination growth and manageable expense levels. Further, the company plans to sell $2 billion in loans in the first quarter of 2025, which should support the updated EPS guide. Arfstrom&#8217;s thesis remains consistent, as he noted continued progress in the gradual shift toward a more balanced growth model. However, additional loan sales and buyback activity will likely continue over the near-to-medium term.
Arfstrom adjusted his 2025E EPS from $2.90 to $3.00 and his 2026E EPS from $3.20 to $3.40. The price target of $32 is ~10.5 times Arfstrom&#8217;s 2025 EPS estimate. The target primarily mirrors the analyst&#8217;s profitability and risk assessment of the company relative to a peer group of similar companies. The assumed multiple is consistent with a peer group of consumer finance-oriented operators.
JP Morgan: SLM reported GAAP and core EPS of $0.50, below Shane&#8217;s estimate of $0.57, and Street estimates of $0.55, driven by elevated provision expense. SLM provided 2025 guidance, which the analyst noted matches expectations.
However, balance sheet growth may exceed the company&#8217;s long-term framework of 5%-6% year-on-year, which could drive incremental reserve build in 2025. There were no loan sales in the fourth quarter of 2024, but the company announced a $2 billion loan sale in the first quarter of 2025, followed by additional loan sales in 2025.
Shane valued SLM based on a forward multiple of core earnings. In determining a December 2025 price target, he applied a multiple of 9.00 times (versus 8.75 times prior) on his 2026 core EPS estimate of $3.32 (versus $3.33 prior). The multiple reflects higher growth potential as SLM continues to take market share. The price target implies a 4.5% potential annualized total return.
Price Action: SLM stock is down 0.27% at $29.22 at last check Friday.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/25/01/43192081/affirm-surges-on-750-million-liberty-mutual-deal-eyes-34-billion-lending-target-for-2025" target="_blank" rel="noreferrer noopener">Affirm Surges on $750 Million Liberty Mutual Deal, Eyes $34 Billion Lending Target for 2025</a></li>
</ul>
Photo by Ground Picture on Shutterstock.

SLM's Loan Growth And Expense Control In Focus, Analysts Adjust Price Forecasts

Biotech

General

EXEL

Exelixis To Present Results From Subgroup Analysis Of Phase 3 CABINET Pivotal Study Evaluating Cabozantinib In Advanced Gastrointestinal Neuroendocrine Tumors Presented At ASCO GI 2025  At 11:30 a.m. PT on January 24; Cabozantinib Reduced The Risk Of Disease Progression Or Death By 50% Compared With Placebo In Patients With Advanced Gastrointestinal Neuroendocrine Tumors

WIIM

PHV shares are trading lower after JP Morgan downgraded the stock from Overweight to Neutral and cut its price target from $149 to $113.

Whales with a lot of money to spend have taken a noticeably bullish stance on Tempus AI.
Looking at options history for Tempus AI (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEM#NASDAQ">TEM</a>) we detected 24 trades.
If we consider the specifics of each trade, it is accurate to state that 50% of the investors opened trades with bullish expectations and 41% with bearish.
From the overall spotted trades, 4 are puts, for a total amount of $158,445 and 20, calls, for a total amount of $1,428,438.
<h3>Projected Price Targets</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $20.0 to $90.0 for Tempus AI during the past quarter. 
<h3>Volume &amp; Open Interest Development</h3>
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Tempus AI's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Tempus AI's significant trades, within a strike price range of $20.0 to $90.0, over the past month.
<h3>Tempus AI 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1737747060_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>TEM</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/16/26</td>
<td>$36.0</td>
<td>$34.4</td>
<td>$35.3</td>
<td>$20.00</td>
<td>$338.8K</td>
<td>1.7K</td>
<td align="right">348</td>
</tr>
<tr>
<td>TEM</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>04/17/25</td>
<td>$5.8</td>
<td>$5.4</td>
<td>$5.5</td>
<td>$70.00</td>
<td>$168.3K</td>
<td>1.3K</td>
<td align="right">544</td>
</tr>
<tr>
<td>TEM</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>02/14/25</td>
<td>$7.6</td>
<td>$6.9</td>
<td>$7.25</td>
<td>$52.00</td>
<td>$163.1K</td>
<td>64</td>
<td align="right">248</td>
</tr>
<tr>
<td>TEM</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>02/07/25</td>
<td>$25.1</td>
<td>$24.8</td>
<td>$24.8</td>
<td>$29.00</td>
<td>$99.2K</td>
<td>2</td>
<td align="right">40</td>
</tr>
<tr>
<td>TEM</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>04/17/25</td>
<td>$5.5</td>
<td>$5.4</td>
<td>$5.5</td>
<td>$70.00</td>
<td>$82.5K</td>
<td>1.3K</td>
<td align="right">238</td>
</tr>
</tbody>
</table>

<h3>About Tempus AI</h3>
Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting data useful. Its Intelligent Diagnostics use AI, including generative AI, to make laboratory tests more accurate, tailored, and personal.
Having examined the options trading patterns of Tempus AI, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Present Market Standing of Tempus AI</h3>
<ul>
<li>Currently trading with a volume of 10,924,277, the TEM's price is down by -4.54%, now at $52.35. </li>
<li>RSI readings suggest the stock is currently may be overbought.</li>
<li>Anticipated earnings release is in 24 days.</li>
</ul>
<h3>Professional Analyst Ratings for Tempus AI</h3>
2 market experts have recently issued ratings for this stock, with a consensus target price of $54.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Needham has revised its rating downward to Buy, adjusting the price target to $56. 
&#x2A; Consistent in their evaluation, an analyst from Loop Capital keeps a Buy rating on Tempus AI with a target price of $52. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Tempus AI, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

Options

Decoding Tempus AI's Options Activity: What's the Big Picture?

Deep-pocketed investors have adopted a bullish approach towards Caterpillar (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAT#NYSE">CAT</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in CAT usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 18 extraordinary options activities for Caterpillar. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 61% leaning bullish and 33% bearish. Among these notable options, 9 are puts, totaling $544,085, and 9 are calls, amounting to $1,054,571.
<h3>Projected Price Targets</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $370.0 to $500.0 for Caterpillar during the past quarter. 
<h3>Insights into Volume &amp; Open Interest</h3>
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Caterpillar's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Caterpillar's whale trades within a strike price range from $370.0 to $500.0 in the last 30 days. 
<h3>Caterpillar Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1737747055_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>CAT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/15/27</td>
<td>$48.2</td>
<td>$46.3</td>
<td>$46.3</td>
<td>$460.00</td>
<td>$416.7K</td>
<td align="right">794</td>
<td align="right">184</td>
</tr>
<tr>
<td>CAT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/15/27</td>
<td>$48.4</td>
<td>$46.3</td>
<td>$46.3</td>
<td>$460.00</td>
<td>$282.4K</td>
<td align="right">794</td>
<td align="right">94</td>
</tr>
<tr>
<td>CAT</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$37.4</td>
<td>$36.4</td>
<td>$37.0</td>
<td>$420.00</td>
<td>$229.4K</td>
<td align="right">5</td>
<td align="right">62</td>
</tr>
<tr>
<td>CAT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/18/26</td>
<td>$53.75</td>
<td>$53.35</td>
<td>$53.75</td>
<td>$420.00</td>
<td>$107.5K</td>
<td align="right">46</td>
<td align="right">22</td>
</tr>
<tr>
<td>CAT</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$11.45</td>
<td>$10.95</td>
<td>$11.15</td>
<td>$405.00</td>
<td>$100.3K</td>
<td align="right">96</td>
<td align="right">100</td>
</tr>
</tbody>
</table>

<h3>About Caterpillar</h3>
Caterpillar is the world's leading manufacturer of construction and mining equipment, off-highway diesel and natural gas engines, industrial gas turbines and diesel-electric locomotives. Its reporting segments are: construction industries (40% sales/47% operating profit, or OP), resource industries (20% sales/19% OP), and energy &amp; transportation (40% sales/34% OP). Market share approaches 20% across many products. Caterpillar operates a captive finance subsidiary to facilitate sales. The firm has global reach (46% US sales/54% ex-US). Construction skews more domestic, while the other divisions are more geographically diversified. An independent network of 156 dealers operates approximately 2,800 facilities, giving Caterpillar reach into about 190 countries for sales and support services.
In light of the recent options history for Caterpillar, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Current Position of Caterpillar</h3>
<ul>
<li>Trading volume stands at 920,464, with CAT's price up by 0.08%, positioned at $406.73.</li>
<li>RSI indicators show the stock to be may be overbought.</li>
<li>Earnings announcement expected in 6 days.</li>
</ul>
<h3>Professional Analyst Ratings for Caterpillar</h3>
A total of 3 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $413.3333333333333.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Citigroup persists with their Buy rating on Caterpillar, maintaining a target price of $420. 
&#x2A; An analyst from Evercore ISI Group upgraded its action to In-Line with a price target of $365. 
&#x2A; An analyst from Truist Securities has decided to maintain their Buy rating on Caterpillar, which currently sits at a price target of $455. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Caterpillar, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

A Closer Look at Caterpillar's Options Market Dynamics

High-rolling investors have positioned themselves bullish on Edwards Lifesciences (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EW#NYSE">EW</a>), and it's important for retail traders to take note. 
\This activity came to our attention today through Benzinga's tracking of publicly available options data. The identities of these investors are uncertain, but such a significant move in EW often signals that someone has privileged information.
Today, Benzinga's options scanner spotted 8 options trades for Edwards Lifesciences. This is not a typical pattern.
The sentiment among these major traders is split, with 100% bullish and 0% bearish. Among all the options we identified, there was one put, amounting to $45,570, and 7 calls, totaling $503,070.
<h3>Expected Price Movements</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $75.0 to $77.5 for Edwards Lifesciences over the last 3 months. 
<h3>Analyzing Volume &amp; Open Interest</h3>
In today's trading context, the average open interest for options of Edwards Lifesciences stands at 54.0, with a total volume reaching 16,185.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Edwards Lifesciences, situated within the strike price corridor from $75.0 to $77.5, throughout the last 30 days.
<h3>Edwards Lifesciences 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1737747050_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>EW</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$1.4</td>
<td>$1.35</td>
<td>$1.35</td>
<td>$75.00</td>
<td>$151.3K</td>
<td align="right">42</td>
<td>1.4K</td>
</tr>
<tr>
<td>EW</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$1.7</td>
<td>$1.55</td>
<td>$1.65</td>
<td>$75.00</td>
<td>$97.2K</td>
<td align="right">42</td>
<td>3.1K</td>
</tr>
<tr>
<td>EW</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$1.6</td>
<td>$1.55</td>
<td>$1.6</td>
<td>$75.00</td>
<td>$81.2K</td>
<td align="right">42</td>
<td>1.8K</td>
</tr>
<tr>
<td>EW</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$1.65</td>
<td>$1.55</td>
<td>$1.65</td>
<td>$75.00</td>
<td>$62.5K</td>
<td align="right">42</td>
<td>4.1K</td>
</tr>
<tr>
<td>EW</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$1.6</td>
<td>$1.55</td>
<td>$1.6</td>
<td>$75.00</td>
<td>$53.1K</td>
<td align="right">42</td>
<td>3.5K</td>
</tr>
</tbody>
</table>

<h3>About Edwards Lifesciences</h3>
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter valve technologies, surgical clips, and catheters. The firm derives about 55% of its total sales from outside the US.
In light of the recent options history for Edwards Lifesciences, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Current Position of Edwards Lifesciences</h3>
<ul>
<li>Currently trading with a volume of 2,056,732, the EW's price is up by 0.45%, now at $69.24. </li>
<li>RSI readings suggest the stock is currently may be oversold.</li>
<li>Anticipated earnings release is in 11 days.</li>
</ul>
<h3>Professional Analyst Ratings for Edwards Lifesciences</h3>
1 market experts have recently issued ratings for this stock, with a consensus target price of $60.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Wolfe Research downgraded its action to Underperform with a price target of $60. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Edwards Lifesciences options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

Smart Money Is Betting Big In Edwards Lifesciences Options

Thornburg Investment Management stepped into the <a href="https://www.benzinga.com/etfs">world of ETFs</a> this week with its first two funds hitting the market. Both the funds focused on international equities.
See Also: <a href="https://www.benzinga.com/etfs/new-etfs/25/01/43129309/new-bond-etf-aims-for-high-income-through-flexible-multi-asset-strategy">New Bond ETF Aims For High Income Through Flexible Multi-Asset Strategy</a>
The first of these funds, the Thornburg International Equity ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TXUE#NASDAQ">TXUE</a>) , was launched on Jan 22. This actively managed fund follows the MSCI EAFE Index. It has a 0.65% expense ratio, and primarily invests in companies tied to developed markets outside the United States. A glimpse into its international holdings reveal some big names like Hitachi Ltd., Mitsubishi UFJ Financial Group, and Keyence Corp. Almost 76% of the total assets is invested in U.S. dollars. The fund uses bottom-up analysis to identify potentially undervalued large-cap equities.
Just a day after the launch of the International Equity ETF, Thornburg rolled out its second ETF, the Thornburg International Growth ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TXUG#NASDAQ">TXUG</a>). This fund has a net expense ratio of 0.70%, is on the third gear to achieve long-term capital growth. 
The International Growth ETF also focuses on developed markets outside the U.S., but has a more growth-oriented strategy, fishing for companies with significant growth potential, regardless of market capitalization.
<h3 class="wp-block-heading">Expanding Horizons</h3>
Thornburg, which oversees more than $45 billion in assets, has built a strong reputation for its active management strategies over the past four decades. The firm also plans to introduce two fixed income ETFs in the near future: the Thornburg Core Plus Bond ETF (TPLS) and the Thornburg Multi-Sector Bond ETF (TMB).
Todd Rosenbluth, Head of Research at VettaFi, noted that the demand for actively managed equity ETFs has surged. "It's exciting to see them bring their expertise to support ETF-minded advisors. Demand for actively managed equity ETFs has accelerated, and VettaFi expects advisors to further embrace such strategies from managers they know."
The company also benefited from the expertise of the Goldman Sachs ETF Accelerator, a platform that powered the launch process for these funds.
See Next: 
<ul>
<li><a href="https://www.benzinga.com/25/01/43170386/spdr-gold-shares-vs-ishares-gold-trust-two-shiny-etfs-in-focus-as-tariff-man-trump-fuels-uncertainty">SPDR Gold Shares Vs. iShares Gold Trust: Two Shiny ETFs In Focus As &#8216;Tariff Man&#8217; Trump Fuels Uncertainty</a></li>
</ul>
Photo: Shutterstock

New ETFs

TXUE

TXUG

Thornburg ETF Debut: First Funds Target Global Equities With Active Strategies

<a href="https://www.bloomberg.com/news/articles/2025-01-24/beacon-roofing-seeks-potential-rivals-to-qxo-takeover-bid" title="https://www.bloomberg.com/news/articles/2025-01-24/beacon-roofing-seeks-potential-rivals-to-qxo-takeover-bid">https://www.bloomberg.com/news/articles/2025-01-24/beacon-roofing-seeks-potential-rivals-to-qxo-takeover-bid</a>
Beacon Roofing Supply Inc. has started soliciting interest from potential buyers as it looks to fend off an $11 billion takeover bid from rival QXO Inc., people familiar with the matter said.

BECN

'Beacon Roofing Seeks Potential Rivals To QXO Takeover Bid' - Bloomberg News

Major indexes are lower amid a drop in chip stocks.

Calamos Investments has introduced a suite of Protected Bitcoin Exchange-Traded Funds (ETFs), designed to offer exposure to Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) while minimizing risk.
What Happened: The flagship ETF provides 100% downside protection over a one-year period, ensuring that investors&#8217; principal remains intact even if Bitcoin experiences a significant price drop. 
However, this safety net comes with a trade-off—an upside cap set at 11.65% for the year.
Understanding that different investors have varying risk preferences, Calamos has rolled out additional ETFs with tailored protection levels.
The first one being: Investors can opt for 90% downside protection, with an estimated upside cap range of 28% to 31% and secondly, those willing to assume more risk, the 80% protection option offers an estimated cap range of 50% to 55%.
How It Works: These ETFs employ a structured investment strategy that combines U.S. Treasury securities and options on the CBOE Bitcoin Index. 
By purchasing zero-coupon Treasuries and strategically buying and selling call options, the funds aim to provide defined exposure to Bitcoin&#8217;s price movements while offering specified levels of downside protection and upside potential.
Why It Matters: As cryptocurrencies continue to see volatile price swings, products like the Calamos Protected Bitcoin ETFs provide a safer way for investors to gain Bitcoin exposure. 
By guaranteeing principal protection while offering varying levels of upside potential, these ETFs aim to bridge the gap between traditional risk-averse investing and the high-reward opportunities of crypto.
However, it's important to note that the capped gains may limit returns in a bull market, making these ETFs more suitable for cautious investors seeking moderate growth with minimized downside risk.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/01/43195587/coinbase-ceo-brian-armstrong-says-bitcoin-is-a-better-form-of-money">Coinbase CEO Brian Armstrong Says Bitcoin Is &#8216;A Better Form Of Money&#8217;</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Forget Worrying About Bitcoin Going Down 50%, There's Now A 'Protected Bitcoin ETF' With Money-Back Guarantee

Royal Caribbean Cruises shares are trading lower after Goldman Sachs cut its price target on the stock from $275 to $270.

WELL

Welltower shares are trading higher after B of A Securities maintained a Buy rating on the stock and raised its price target from $190 to $221.

Three <a href="https://www.benzinga.com/topic/chinese-ev-stocks" target="_blank" rel="noreferrer noopener">Chinese electric vehicle makers</a> contested the <a href="https://www.benzinga.com/markets/equities/24/10/41182675/tesla-byd-and-other-ev-stocks-to-watch-as-eu-votes-to-approve-tariffs-on-chinese-ev-imports" target="_blank" rel="noreferrer noopener">EU&#8217;s import duties</a> at the union&#8217;s Court of Justice. 
According to Reuters, BYD Co (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BYDDF#OTC">BYDDF</a>) (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BYDDY#OTC">BYDDY</a>), Geely Automobile Holdings (OTC:<a class="ticker" href="https://www.benzinga.com/stock/GELYF#OTC">GELYF</a>) (OTC:<a class="ticker" href="https://www.benzinga.com/stock/GELYY#OTC">GELYY</a>), and SAIC Motor (Shanghai Automotive Industry Corporation) oppose EU-<a href="https://www.benzinga.com/news/24/10/41311787/tesla-rival-byd-slams-eu-tariffs-on-chinese-evs-needs-more-positive-education-trust-is-low" target="_blank" rel="noreferrer noopener">imposed taxes</a>. BYD has a 17% tariff, Greely 18.8%, and SAIC, 35.3% (in addition to its car import duty of 10%).
After an anti-subsidy investigation, the EU imposed a tax&nbsp;on China-made EVs in October.
Also Read: <a href="https://www.benzinga.com/government/regulations/25/01/43155691/amazon-to-shut-7-quebec-fulfillment-centers-axe-around-2000-jobs" target="_blank" rel="noreferrer noopener">Amazon To Shut 7 Quebec Fulfillment Centers, Axe Around 2,000 Jobs</a>
China-based EV makers flagged the exclusion of leading EV exporter Tesla Inc&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) from the additional tariffs.
Tesla bagged the lowest extra tariff of 7.8%.
<a target="_blank" href="https://www.benzinga.com/tech/25/01/43187706/teslas-chinese-rivals-xpeng-li-auto-nio-rise-in-premarket-trading-after-trumps-friendly-conversation-with-xi-jinping-we-have-one-very-big-power-over-chinaid-rather-not" rel="noreferrer noopener">U.S.-listed Chinese EV stocks</a>&nbsp;Li Auto Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LI#NASDAQ">LI</a>),&nbsp;Nio Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NIO#NYSE">NIO</a>), and&nbsp;Xpeng Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPEV#NYSE">XPEV</a>) surged Friday after President&nbsp;Donald Trump&nbsp;hinted in an interview that he would instead not use tariffs against China.
<a href="https://www.benzinga.com/markets/25/01/43091254/teslas-chinese-rivals-li-xpeng-nio-surge-while-rivian-declines-in-pre-market-as-trump-revokes-bidens-ev-target" target="_blank" rel="noreferrer noopener">Also this week</a>, Trump repealed former President Joe Biden&#8216;s order ensuring that 50% of new vehicles sold in the U.S. by 2030 are electric. Trump also weighed ending the $7,500 federal tax credit available on EV purchases.
<a href="https://www.benzinga.com/markets/emerging-markets/24/12/42700628/chinas-ev-price-wars-hit-auto-profits-smaller-players-struggle-as-margins-shrink" target="_blank" rel="noreferrer noopener">China's car market</a>, particularly the EV sector, has faced fierce competition over the past two years, sparking a price war. Projections suggest China will lead global EV adoption by 2025, with EV sales expected to outpace traditional cars for the first time. The country will likely sell over 12 million EVs in 2025, doubling 2022 figures, while traditional car sales may fall below 11 million. Reports also reveal plans for China to issue 3 trillion yuan ($411 billion) in special treasury bonds in 2025 to boost consumption through subsidies, equipment upgrades, and investments in the EV sector.
Investors can gain exposure to stocks of companies that are domiciled in China through iShares China Large-Cap ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FXI#NYSE">FXI</a>) and KraneShares Trust KraneShares CSI China Internet ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KWEB#NYSE">KWEB</a>).
Also Read:
<ul>
<li><a href="https://www.benzinga.com/25/01/43139681/himax-to-gain-big-as-tsmc-nvidia-and-amd-advance-silicon-photonics-and-coupe-tech-analyst" target="_blank" rel="noreferrer noopener">Himax To Gain Big As TSMC, Nvidia and AMD Advance Silicon Photonics and COUPE Tech: Analyst</a></li>
</ul>
Image: Shutterstock

Government

Regulations

Legal

Media

BYDDF

BYDDY

GELYF

GELYY

KWEB

TSLA

XPEV

BYD, Geely, SAIC Contest EU's High EV Tariffs In Court

Market Summary

Benzinga Market Summary: S&P Pulls Back, Texas Instruments Stock Falls On Soft Guidance, Bitcoin Rises

Press Releases

AllStar Health Brands Inc. Acquires Major Interest in Italian Football Club Sanremo; Expands Sports Operations to North America

12 OTC Stocks to Watch: Clean Vision Corporation (OTCQB: CLNV), NaturalShrimp Inc (OTCQB: SHMP), Northwest Biotherapeutics, Inc. (OTCQB: NWBO), and More

Stocks Under 1¢ to Watch Now! SPZI, HALB, DPLS, RSHN, ALST, ZRFY

AllStar Health Brands Inc (OTC:ALST) Targets Miami for New State-of-the-Art Soccer Complex, Aiming to Elevate Youth Development to International Standards

AllStar Health Brands Inc (OTC:ALST) Targets Italy Level 2 Soccer Club in Italy

AllStar Health Brands / AllStar Global Brands Sign Enzo Concina Pro Scout and Senior Italian Consultant

Allstar Health Brands, Inc. (ALST) Engages in Strategic Acquisition Negotiations with MergersCorp Investment Banking for Italian Soccer Team

CFTN

CLNV

DPLS

ENZC

GEVI

HALB

HNRC

NWBO

RSHN

SHMP

SPZI

ZRFY

AllStar Health Brands

Sibannac, Inc. (OTC:<a class="ticker" href="https://www.benzinga.com/stock/SNNC#OTC">SNNC</a>), an Arizona-based company that manufactures and sells wellness products in the CPG space&nbsp;is making strategic moves in the burgeoning <a href="https://www.benzinga.com/markets/cannabis/23/09/34548455/medical-cannabis-in-canada-faces-decline-whats-behind-the-38-drop-in-registrations">cannabis</a> and wellness market.

The company <a href="https://www.newsfilecorp.com/release/182010/Sibannac-Inc.-Signs-Heads-of-Terms-Agreement-with-Allstar-HealthTyme-Cannabis-to-Enter-the-Canadian-Cannabis-Retail-Market?k=cannabis">reported </a>it has signed an agreement with AllStar Health Brands Inc. (OTC:<a class="ticker" href="https://www.benzinga.com/stock/ALST#OTC">ALST</a>) to explore the acquisition of retail cannabis franchises in Ontario, Canada.

<h3>Expanding Footprint And Diverse Product Offerings</h3>

Already in a Joint Venture Strategic Partnership with Tyme Cannabis Co., AllStar plans to add over 70 new cannabis retail locations throughout Ontario, pending regulatory approval.

These expansions will operate under Tyme&#39;s AGCO license, leveraging their established operational base in Hamilton, Ontario.

Sibannac&#39;s collaboration with the AllStar-Tyme group outlines the initial acquisition of up to five locations within the first year.

This partnership also opens doors for Sibannac to introduce kratom products into the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/23/09/34080722/cannabis-flower-market-shifts-zuanic-associates-highlight-growth-amid-changing-tren">Canadian market</a>, without the need for additional licensing.

The company&#39;s diverse product portfolio includes kratom, hemp-derived Delta-8/9 products&nbsp;and Amanita mushroom edibles that&nbsp;cater&nbsp;to both wholesale and retail markets. Sibannac also offers contract manufacturing and white labeling services while actively developing and managing its own <a href="https://www.benzinga.com/analyst-ratings/analyst-color/23/08/34080818/canadian-cannabis-flower-power-who-are-the-top-players-what-happened-in-q2-2023">brands</a>.

Sibannac&#39;s Scottsdale retail location is set to open by December 2023. The AllStar-Tyme alliance will handle operations and store build-outs for new franchisees, providing a &quot;turn-key&quot; retail solution.

Want to watch our Cannabis Capital Conference live? For existing subscribers, you can get direct access&nbsp;<a href="https://www.benzinga.com/research/cannabis-capital-conference" rel="noopener noreferrer" target="_blank">through our research platform</a>. For new users, you can get&nbsp;<a href="https://www.benzinga.com/premium/ideas/sales-landing-2-2/" rel="noopener noreferrer" target="_blank">instant access here</a>!

Photo by&nbsp;<a href="https://unsplash.com/@hermez777?utm_source=unsplash&amp;utm_medium=referral&amp;utm_content=creditCopyText">Hermes Rivera</a>&nbsp;on&nbsp;<a href="https://unsplash.com/photos/aJ8F0SmOBpY?utm_source=unsplash&amp;utm_medium=referral&amp;utm_content=creditCopyText">Unsplash</a>.&nbsp;

Comments

AllStar Health Brands

News

Latest news for AllStar Health Brands (OTC:ALST) Stock

Friday, September 29, 2023

Tuesday, March 24, 2020

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga